Drugs / rSm14
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01154049 | Mar 2011 → Apr 2014 | schistosomiasis | Oswaldo Cruz Foundation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05658614 | Jul 2022 → Sep 2023 | Schistosoma mansoni infectious disease | Oswaldo Cruz Foundation | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rSm14 | “Safety and immunogenicity of a recombinant 14kDa, fatty acid-binding protein(FABP) from Schistosoma mansoni (rSm14) were evaluated through an open, non-placebo-controlled,...” PMID 26571311 ↗ Nov 20151“rSm14 - recombinant protein (GMP produced) - 50ug / injection” NCT05658614 ↗ |
| Modality | Protein / enzyme biologic | “a recombinant 14kDa, fatty acid-binding protein(FABP) from Schistosoma mansoni (rSm14)” PMID 26571311 ↗ Nov 2015 |
| Route | Intramuscular | “were given intramuscularly three times with 30-day intervals” PMID 26571311 ↗ Nov 2015 |